What is IOBT's current stock price?

IOBT (IO Biotech, Inc.) is currently trading at $0.01 with a market cap of $885.7K.

What sector is IO Biotech, Inc. in?

IO Biotech, Inc. (IOBT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IOBT a good stock to buy?

Analysts have a Hold consensus on IOBT with a price target of $0.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IOBT IO Biotech, Inc.

Healthcare

$0.01-27.59%ClosedMarket Cap: $885,690

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.90

P/S

0.00

EV/EBITDA

0.32

DCF Value

$0.83

FCF Yield

-9152.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-465.4%

ROA

-221.1%

ROIC

-406.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$0.00	$-8.4M	$—
Q2 null	$0.00	$-26.2M	$—
Q1 null	$0.00	$-22.4M	$—
Q4 null	$0.00	$-31.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$0.50

Target (Median)

$0.50

Target Range

$0.50 - $0.50

0 Strong Buy1 Buy2 Hold1 Sell0 Strong Sell

Piper SandlerNeutral

2026-01-26

Piper SandlerOverweight

2025-10-22

TD CowenHold

2025-09-30

HC Wainwright & Co.Neutral

2025-09-29

Morgan StanleyOverweight

2025-08-12

Trading Activity

Insider Trades

View All

Smith David Vdirector

SellFri Jun 06

Hunter Heididirector

SellFri Jun 06

Hirth Peterdirector

SellFri Jun 06

Glaub Kathleen Seredadirector

SellFri Jun 06

Elling Christian Edirector

SellFri Jun 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.89

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Peers

CUE